Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Feb 1, 2018
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.408 billion during the fourth quarter ended December 31, 2017. This represents growth of 9.9 percent on a reported basis and 8.1...
-
Jan 29, 2018
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the LEERINK Partners 7th Annual Global Healthcare Conference on February 15, 2018 in New York. Dan Brennan, executive vice...
-
Jan 24, 2018
Boston Scientific commends the efforts of key champions in the U.S. House and Senate for their successful efforts to suspend the medical device tax, allowing the device industry to reinvest in...
-
Jan 24, 2018Millipede, Inc. is developing the IRIS Transcatheter Annuloplasty Ring System to treat severe mitral regurgitation
Boston Scientific Corporation (NYSE: BSX) today announced it has closed an investment and entered into an acquisition option agreement with Millipede, Inc., a privately-held company that has...
-
Jan 19, 2018
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2017 on Thursday, February...
-
Jan 12, 2018Randomized controlled trial demonstrates effectiveness of long-term treatment with sub-perception spinal cord stimulation
Boston Scientific Corporation (NYSE: BSX) today announced positive results from the WHISPER randomized controlled trial (RCT). The data, presented at the 2018 Annual Meeting of the North American...
-
Jan 11, 2018System offers non-opioid treatment option with multiple therapies for people with chronic pain
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Spectra WaveWriter™ Spinal Cord Stimulator (SCS) System. It is the...
-
Jan 9, 2018
Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.41 billion during the fourth quarter ended December 31, 2017....
-
Dec 22, 2017
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 36th annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 in San Francisco, CA. Mike Mahoney, chairman...
-
Dec 21, 2017
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday, January 4, 2018 in Boston, MA. Mike Mahoney, chairman...
-
Dec 11, 2017Platform Offers Physicians Advanced Technology to Treat Symptoms of Parkinson's disease
Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the Vercise™ Deep Brain Stimulation (DBS) System. DBS...
-
Dec 4, 2017
Boston Scientific Corporation (NYSE: BSX) will participate in the BMO Capital Markets Prescriptions for Success Healthcare Conference on December 14, 2017 in New York. Susie Lisa, vice president,...
-
Nov 28, 2017
Boston Scientific (NYSE: BSX) announces a delay to previously communicated timelines for commercialization of the LOTUS Edge™ Aortic Valve System* in Europe and the U.S. After initiating a...
-
Nov 27, 2017
Boston Scientific Corporation (NYSE: BSX) will participate in the Citi 2017 Global Healthcare Conference on December 7, 2017 in New York. Kevin Ballinger, executive vice president and president,...
-
Nov 13, 2017
Boston Scientific Corporation (NYSE: BSX) will participate in the Piper Jaffray 29th Annual Healthcare Conference on November 28, 2017 in New York. Susie Lisa, vice president, investor relations...
-
Nov 8, 2017American Heart Association, American College of Cardiology and Heart Rhythm Society Issue Updated Guidelines Underscoring Benefits of the S-ICD System
Updated guidelines issued by the American Heart Association (AHA), the American College of Cardiology (ACC) and the Heart Rhythm Society (HRS) now formally recommend the use of a subcutaneous...
-
Nov 8, 2017
Boston Scientific Corporation (NYSE: BSX) will participate in the Stifel 2017 Healthcare Conference on November 14, 2017 in New York. Dan Brennan, executive vice president and chief financial...
-
Nov 6, 2017
Boston Scientific Corporation (NYSE: BSX) will participate in the 26th Annual Credit Suisse Healthcare Conference on November 7, 2017 in Scottsdale, Arizona. Joe Fitzgerald, executive vice...
-
Nov 2, 2017Late-breaking Clinical Trial Data Presented at TCT 2017 with Simultaneous Publication in the Journal of the American College of Cardiology
Boston Scientific (NYSE: BSX) announced final five-year outcomes data from the PREVAIL study of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device today during a late-breaking clinical...
-
Oct 26, 2017
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.222 billion during the third quarter ended September 30, 2017. This represents growth of 5.6 percent on a reported basis and 5.7...
-
Oct 23, 2017
Boston Scientific (NYSE: BSX) today announced key data that will be presented at the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular...
-
Oct 4, 2017
Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Desiree Ralls-Morrison as senior vice president, general counsel and corporate secretary. Ralls-Morrison will join...
-
Oct 2, 2017Acquisition to Strengthen Company's Electrophysiology Portfolio and Expand into "Single-Shot" Balloon Pulmonary Vein Isolation Treatments for Patients with Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Apama Medical Inc., a privately-held company that is developing the Apama Radiofrequency (RF) Balloon...
-
Oct 2, 2017
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2017 on Thursday, October...
-
Sep 25, 2017
Boston Scientific (NYSE: BSX) has launched the Resonate™ family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems featuring the...
-
Sep 19, 2017Data Presented at Heart Failure Society of America's 21st Annual Scientific Meeting Demonstrate Alert Improves Heart Failure Risk Prediction
Boston Scientific (NYSE: BSX) today announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients (MultiSENSE) study evaluating the performance of the...
-
Sep 18, 2017Patients with Severe Asthma Show Sustained Clinical Improvement
Boston Scientific (NYSE: BSX) today announced results from a three year follow-up cohort in its Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma...
-
Aug 28, 2017
Boston Scientific Corporation (NYSE: BSX) will participate in the Morgan Stanley Global Healthcare Conference on September 12, 2017 in New York City. Mike Mahoney, chairman and chief executive...
-
Aug 21, 2017
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Wells Fargo Healthcare Conference on September 7, 2017 in Boston. Susie Lisa, vice president, Investor Relations, will...
-
Jul 31, 2017
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Canaccord Genuity Growth Conference on August 9, 2017 in Boston. Boston Scientific investor relations representatives,...
-
Jul 27, 2017
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.257 billion during the second quarter ended June 30, 2017. This represents growth of 6 percent on a reported basis and 7 percent on...
-
Jul 5, 2017
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2017 on Thursday, July 27, 2017 at
-
Jun 27, 2017
Boston Scientific Corporation (NYSE: BSX) is hosting a meeting with the investment community today in New York City to provide an overview of its business and long-term growth strategies. Chairman...
-
Jun 6, 2017Industry's First MR-Conditional Directional DBS System with Stimulation Visualization
Boston Scientific (NYSE: BSX) has received CE mark for the Vercise™ Gevia™ Deep Brain Stimulation (DBS) System*, a rechargeable, magnetic resonance (MR) conditional device indicated for the...
-
May 24, 2017Results from Evaluation of Real-World Patients Presented at American Thoracic Society International Conference
Boston Scientific (NYSE: BSX) today announced positive results from the Post Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma (PAS2) study evaluating...
-
May 17, 2017
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2017 UBS Global Healthcare Conference on Tuesday, May 23, 2017 in New York City. Susie Lisa, vice president, investor...
-
May 16, 2017
Boston Scientific (NYSE: BSX) today announced positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific Program, in Paris. Data from the study demonstrated...
-
May 16, 2017Acquisition Expands Company's Structural Heart Portfolio; Increases Offerings for the Treatment of Patients with Valvular Heart Disease
Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter...
-
May 12, 2017Largest Prospective Study of the WATCHMAN Device Presented as Late-Breaking Trial at Heart Rhythm 2017
Boston Scientific (NYSE: BSX) today announced positive safety and efficacy rates of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry presented during a...
-
May 12, 2017Analyses Evaluated the Impact of Ethnicity, Gender and Income on Cardiovascular Outcomes
New analyses from the Boston Scientific Corporation (NYSE: BSX) sponsored PLATINUM Diversity study underscore the need for greater understanding of the clinical and nonclinical barriers that can...
-
May 11, 2017Late-Breaker Data Presented at Heart Rhythm 2017
Boston Scientific (NYSE: BSX) today announced results from the U.S. post-market approval study evaluating 'real-world' patients implanted with the Subcutaneous Implantable Defibrillator (S-ICD)...
-
May 10, 2017Pivotal Data From REPRISE III and EWOLUTION Among Four Late-breaking Clinical Trials to be Presented
Boston Scientific (NYSE: BSX) today announced the schedule of key data presentations, including four late-breaking clinical trials, that will be featured at the annual EuroPCR Scientific Program,...
-
May 9, 2017New Devices Combine Longest-Lasting Battery Technology, Therapy Optimization and HeartLogic™ Heart Failure Diagnostics
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Resonate™ family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization...
-
May 3, 2017Late-Breaking Clinical Trials Feature Subcutaneous Implantable Defibrillator and WATCHMAN™ Left Atrial Appendage Closure Device
Boston Scientific (NYSE: BSX) today announced the schedule of key data presentations, including two late-breaking clinical trials, that will be featured at the 38th Annual Scientific Sessions of...
-
May 1, 2017
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2017 Healthcare Conference on Thursday, May 18, 2017 in Las Vegas. Susie Lisa, vice...
-
Apr 27, 2017
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.160 billion during the first quarter ended March 31, 2017. This represents growth of 10 percent compared to the prior year period on...
-
Apr 18, 2017MADIT S-ICD Trial to Study EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System; Trial Recruitment Part of Pilot Initiative to Increase Percentage of Females Enrolled in Clinical Studies
Boston Scientific (NYSE: BSX) has initiated a worldwide study that will evaluate the survival benefit of patients treated with the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD)...
-
Mar 30, 2017
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2017 on Thursday, April 27,...
-
Mar 30, 2017Acquisition Will Expand Treatments for Patients with Valvular Heart Disease and Strengthen Company's Position in Structural Heart Globally
Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter...
-
Mar 16, 2017Extended battery life of Boston Scientific devices attributed to reduction in replacement procedures and complications; has potential for significant cost savings
Today, the National Institute for Health and Care Excellence (NICE) issued medical technology guidance recommending the use of Boston Scientific Corporation (NYSE: BSX) cardiac resynchronization...